Publicaciones en colaboración con investigadores/as de Stony Brook University (8)

2024

  1. Prospective Cohort Study to Compare Long-Term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a–b; ≤20 mm) NSCLC Treated by Stereotactic Body Radiation Therapy and Surgery

    Journal of Thoracic Oncology, Vol. 19, Núm. 3, pp. 476-490

2021

  1. Pharoh lncrna regulates myc translation in hepatocellular carcinoma via sequestering tiar

    eLife, Vol. 10

2019

  1. Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development (Nature Immunology, (2019), 20, 11, (1409-1413), 10.1038/s41590-019-0503-1)

    Nature Immunology

  2. Identification of resistance pathways specific to malignancy using organoid models of pancreatic cancer

    Clinical Cancer Research, Vol. 25, Núm. 22, pp. 6742-6755

  3. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas

    Blood, Vol. 133, Núm. 22, pp. 2401-2412

  4. ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

    Nature Immunology

2015

  1. Organoid models of human and mouse ductal pancreatic cancer

    Cell, Vol. 160, Núm. 1-2, pp. 324-338

2007

  1. Computed tomographic screening for lung cancer: Individualising the benefit of the screening

    European Respiratory Journal, Vol. 30, Núm. 5, pp. 843-847